LETTERS

GP use of anti-D

Madam,

Rhesus haemolytic disease of the newborn is now a rare condition. Deaths from it in England have fallen from 18.4 per 100,000 live births in 1977 to 1.3 per 100,000 in 1992. This improvement is partially due to the use of anti-D immunoglobulin in Rhesus negative women who have bled in early pregnancy. Vaginal bleeding is common, occurring in about 21% of all pregnancies and 11-16% of pregnancies miscarry. Early pregnancy bleeding is investigated and managed in primary care, one recent study showing only 45% of women being admitted to hospital. Therefore, the responsibility for prevention of Rhesus is immunisation has transferred in a large part to general practice.

We are writing to enquire into the use of anti-D in the management of early pregnancy bleeding in a training general practice in Exeter, Devon. The practice population is 6430.

A computer search revealed 73 women who had early pregnancy bleeding between 1994 and 1998. Twenty-eight were excluded because their miscarriage had occurred before they had registered with the practice or because they had self-referred to the Accident and Emergency department. The remaining 45 women had had 61 episodes of early pregnancy bleeding presenting in general practice, and 25 of these episodes were managed solely in primary care. Of the 61 episodes, 12 were in women who were Rhesus negative, and four of these were managed solely in primary care. None of these four received anti-D.

Five of the eight admitted to hospital had anti-D administration documented on their discharge summary. The other three may have received anti-D, but this is unknown. Therefore, between four and seven women (7-11%) received inadequate care.

The results of this study will not be applicable to all general practices. However, questionnaire surveys suggest that over 70% of GPs do not administer anti-D routinely, and their results are likely to be similar. If GPs are to continue managing early pregnancy bleeding in the community, then they need a protocol which incorporates the determination and recording of the woman’s blood group early in pregnancy. Furthermore, supplies of anti-D will need to be easily available within the practice. Without such a protocol, we may see a rise in haemolytic disease of the newborn, which should have been preventable.

Catherine Goulding, BM BS
General Practitioner Registrar

William Hamilton, MRCGP, MRCP
General Practitioner Trainer
Barnfield Hill Surgery, Exeter, Devon, UK

References

Levonorgestrel IUS in use in Malaysia

Madam,

I would like to make some observations relating to the use of the levonorgestrel intra-uterine system in Malaysian hospitals.

Muslims have a religious duty to pray five times a day, and no longer observe Ramadan. They are forbidden to pray or fast during menstruation as blood is considered a pollutant in the context of Islamic practice. The levonorgestrel system may prevent Muslims from carrying out their religious obligations, due to the initial side effects of irregular breakthrough bleeding that may persist during the first 6 months of use.

The benefit of a 20% amenorrhoea rate in the first year of use of the intra-uterine system has propelled it to be used on some patients in Malaysia. Culturally, there is a widespread belief that the act of menstruation relieves the body of its toxins. When amenorrhoea occurs, some patients interpret this as a build up of toxins in their body, despite reassurance to the contrary. The consequences for their partners and children are unknown. Therefore, additional counseling is pertinent prior to the use of the levonorgestrel intra-uterine system to improve the acceptance and compliance rate. An alternative method should always be made available to those who decline the levonorgestrel intra-uterine system.

Chin Yuan Wong, MRCGP, MRCOG, DFPP
Lecturer, Dept of Obstetrics and Gynaecology,
University of Malaya, Kuala Lumpur, Malaysia

Psychological effects of sterilisation in India

Madam,

Female sterilisation is the most widely accepted method of contraception all over the world. In developing countries like India, the majority of women accept this method of contraception are young, uneducated, poor and from a rural background. The decision to undergo sterilisation is usually not their own, but is imposed on them by their mother-in-law, husband or some elder in the family. We have observed that a large number of these women subsequently report to the gynaecology out-patient department with vague symptoms like pain in the abdomen, backache, increase in weight or weakness.

We carried out a study with the aim of comparing the psychological aftermath of female sterilisation amongst rural and urban Indian women. We studied 50 sterilised rural women and 50 sterilised urban women served as controls.

We assessed each of these women, using a rating scale, at the time of their sterilisation as part of the Medical Education (ROME) programme. We found that there was a very high incidence of depression (72%) in rural women compared to only 8% in urban women. The difference was statistically highly significant (p<0.001).

We also found that there was a marked incidence of somatic manifestations such as somatic anxiety and gastrointestinal symptoms in both groups. We feel that there should be detailed counselling of all women before sterilisation, especially in rural areas. Health workers should help women to make a free, proper and correct choice of contraceptive method to be used. This will go a long way to reducing feelings of regret and other long term psychological aftermaths of sterilisation.

Manju Puri
Department of Obstetrics and Gynaecology,
LHMC & SSKH, New Delhi, 110001, India

Forgotten IUDs

Madam,

I read with interest the case report on the forgotten IUD.1 Even though IUDs are supposed to be removed after a variable period of time, some women do not even remember that they have one. During the past 12 months I have come across two patients who were referred to the clinic to rule out malignancy, but who turned out to have forgotten IUDs.

Case 1

A 48-year-old lady was referred by her GP with perimenopausal bleeding. She told us that she vaguely remembered that a Lippes loop was inserted 20 years ago but that she later forgot about it. After she was discharged, her threads were found embedded in the cervical mucosa. Attempts to retrieve the loop in clinic were abandoned because of pain. She underwent hysterectomy, D&C and removal of the IUD. No co-existing intra-uterine pathology was found clinically or histologically. The loop was then confined to the uterus and was removed by hysteroscopy following the removal of the IUD.

Case 2

A 70 year old lady was referred to us with postmenopausal bleeding. She had never had a smear. Outpatient examination revealed a highly suspicious looking cervix. She underwent a cervical biopsy and hysteroscopy. During hysteroscopy a Lippes loop was found confined to the uterine cavity and was removed. Biopsy from cervix and endometrium showed only chronic inflammatory changes.

In both these cases no actinomyces-like organisms were isolated. Although rare, forgotten IUDs can present with ominous symptoms and signs that are worrisome to both the doctor and the patient.

Raje V Vijayanand
Senior SHO, Tameside General Hospital,
Ashton Under Lyne, Lancashire, UK

Depo Provera - irregular bleeding management

Madam,

We are writing in response to the paper on the clinical use, effectiveness and side effects of Depo Provera (DMPA), recently published in The British Journal of Family Planning.1 We feel that there should be detailed counselling of all women before sterilisation, especially in rural areas. Health workers should help women to make a free, proper and correct choice of contraceptive method to be used. This will go a long way to reducing feelings of regret and other long term psychological aftermaths of sterilisation.

Reference

In both these cases no actinomyces-like organisms were isolated. Although rare, forgotten IUDs can present with ominous symptoms and signs that are worrisome to both the doctor and the patient.
combined oral contraceptive pill, or conjugated equine oestrogen, or an oestrogen patch for prolonged bleeding. However Said et al, in a placebo controlled trial of 278 women requesting treatment for bleeding disturbances with DMPA, found that 93% stopped bleeding during treatment with 50 mcg of ethinyl oestradiol (EE) with 2.5 mg of oestrone sulphate and 74% with placebo. This amounted to only one less bleeding day and three less spotting days per 90-day reference period with EE compared to oestrone or placebo. There was no residual benefit from treatment. In fact, those who had taken EE had more unpredictable bleeding in subsequent months. In the long term, the groups did not differ in bleeding patterns, or in discontinuation rates for menstrual disturbance. The message from this is that there is currently no effective long-term treatment for the management of bleeding disturbances with progesterone-only contraception. Since the absence of oestrogen is a major health advantage of these contraceptives for some women, there is currently insufficient evidence to advise its use in DMPA users. Counselling before and during bleeding disturbances should remain the cornerstone of management.

Similarly, the authors recommend earlier administration of the next DMPA injection. We are not aware of any published evidence that this is effective.

The mechanisms of irregular bleeding in progesterone-only contraception are unclear, although recent evidence points towards endometrial vascular fragility at the end point of local changes in vascular integrity. Until these mechanisms are understood, it is unlikely that effective treatment for this troublesome bleeding will be available.

Martha Hickey
Catherine M Paterson
Obstetrics and Gynaecology, Imperial College School of Medicine, Norfolk Place, London, UK

Comments on Implanon review
Madam,
The recent review of Implanon by Edwards and Moore is well timed as it coincides with the withdrawal of the alternative implant, Norplant. One of the main problems with implant technology appears to have been resolved; insertion and removal of the new implant appear to be much easier. In their review of randomised controlled trials comparing Implanon and Norplant. The data on discontinuations with Norplant, however, were not available to the authors. The comparison between the two implants in the European studies is provided in the pooled analysis by Affandi. The discontinuation rate due to bleeding irregularities was 26% in the 129 Implanon users compared to 19% in a similar number of users of Norplant. We are not told if this difference is statistically significant, but it does suggest that the problem of bleeding irregularities may be higher in Implanon users. The introduction of new contraceptive methods benefits from realistic expectations based on good clinical science.

Paul A O’Brien
Senior CMO in Clinical Effectiveness, Services for Women, Parkside Health NHS Trust, St Charles Hospital, Emaoor St, London, UK
PaulOBrien@care.prestel.co.uk

Letters to the editor are welcome and should not normally be longer than 400 words or have more than five references and type should be double spaced. Except in exceptional circumstances, correspondence should be received within 4 weeks of the despatch of the most recent Journal. Correspondents should state their qualifications and address.